
Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer's disease (AD) who were α-synuclein positive, a subgroup associated with higher amyloid burden and faster clinical decline
TOKYO and CAMBRIDGE, Mass., Nov. 19, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that findings from an analysis of lecanemab-irmb (generic name; U.S. brand name: LEQEMBI®) treatment and α-synuclein (α-Syn) co-pathology* in the cerebrospinal fluid (CSF) substudy of Clarity AD in early Alzheimer's disease (AD) were presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, held in Boston and online.

In AD, α-Syn co-pathology may be present alongside amyloid beta (Aβ) and tau pathologies. α-Syn co-pathology may contribute to clinical heterogeneity and disease progression in AD, but its clinical relevance in patients with early AD receiving amyloid-targeting therapy remains unclear. In Clarity AD, lecanemab demonstrated statistically significant slowing of clinical decline in participants with early AD. This post hoc analysis evaluated the prevalence of α-Syn co-pathology and the clinical characteristics associated with α-Syn co-pathology and examined changes over time in clinical assessment scores in the lecanemab and placebo groups in the overall α-Syn-tested group and the α-Syn-positive (α-Syn+) group. These findings were presented in an oral presentation "Lecanemab Treatment and α-Synuclein Co-Pathology in the Clarity AD CSF Substudy" (OC50).
Overview of the Clarity AD CSF Substudy Analysis
A total of 623 CSF samples collected from Clarity AD participants at screening or baseline were assessed using the Amprion SYNTap seed amplification assay (SAA)**. α-Syn status was determined based on the detection of α-Syn seeds in CSF and used as an indicator of α-Syn co-pathology in the brain. Among the Aβ-positive (Aβ+) participants who were randomized to lecanemab or placebo and had α-Syn test results available, 400 were included in the α-Syn-tested group.
Key Findings
Eisai serves as the lead for lecanemab's development and regulatory submissions globally, with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority
* |
α-Synuclein (α-Syn) is a protein abundant in nerve cells that plays a role in signaling at synapses. Abnormally structured α-Syn can aggregate and form deposits called Lewy bodies. Lewy bodies are a pathological hallmark of Parkinson's disease and dementia with Lewy bodies. In AD, α-Syn-related pathology may coexist with amyloid- and tau-related pathology in the same individual. This is referred to as α-Syn co-pathology. |
** |
The Amprion SYNTap seed amplification assay (SAA) detects abnormally structured α-Syn aggregates in a sample by using them as seeds and amplifying their reaction in vitro. |
*** |
The Centiloid (CL) scale standardizes brain amyloid burden measured by amyloid PET; higher values indicate greater amyloid burden. The scale is anchored at 0 CL (the mean in young adults without amyloid plaques) and 100 CL (the mean in people with moderate AD). The mean baseline value in Clarity AD was approximately 78 CL. Plaque negativity was defined as conversion to amyloid PET-negative status (<30 CL). |
**** |
CDR-SB assesses overall clinical status, including cognitive and daily functioning; lower scores indicate better status. ADAS-Cog14 assesses cognitive function; lower scores indicate better status. ADCS MCI-ADL assesses daily functioning and independence in people with mild cognitive impairment (MCI). |
MEDIA CONTACTS |
|
Eisai Co., Ltd. |
Biogen Inc. |
Public Relations Department |
Madeleine Shin |
TEL: +81 (0)3-3817-5120 |
+1-781-464-3260 |
Eisai Europe, Ltd. |
|
EMEA Communications Department |
|
+44 (0) 797 487 9419 |
|
Eisai Inc. (U.S.) |
|
Julie Edelman |
|
+1-862-213-5915 |
|
INVESTOR CONTACTS |
|
Eisai Co., Ltd. |
Biogen Inc. |
Investor Relations Department |
Tim Power |
TEL: +81 (0) 3-3817-5122 |
+ 1-781-464-2442 |
Notes to Editors
References
View original content to download multimedia:https://www.prnewswire.com/news-releases/clarity-ad-csf-substudy-findings-on-lecanemab-treatment-and--synuclein-co-pathology-presented-at-ctad-2026-302945650.html
SOURCE Eisai Inc.